GleamWall
中文EN

TRVI Trevi Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1563880 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY-8.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-24.7%
ROA-23.8%
ROIC (approx.)-27.2%
Asset turnover—

Leverage & solvency

Liabilities / assets2.6%
Debt / equity0.00x
Current ratio38.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$19.06M$15.15M$9.94M$6.19M$10.09M$9.39M$7.81M$9.33M
SG&A expense$5.42M$5.36M$4.97M$4.03M$3.83M$4.33M$3.66M$2.92M
Operating income-$24.49M-$20.51M-$14.91M-$10.22M-$13.92M-$13.72M-$11.47M-$12.24M
Interest expense———$0$0$0—$1,000
Pretax income-$21.47M-$17.82M-$13.21M-$8.33M-$11.82M-$12.32M-$10.35M-$11.40M
Income tax-$19,000-$19,000-$20,000-$16,000-$15,000-$21,000-$11,000$16,000
Net income-$21.45M-$17.80M-$13.19M-$8.32M-$11.80M-$12.30M-$10.34M-$11.41M
EBITDA-$24.45M-$20.48M-$14.88M-$10.19M-$13.88M-$13.68M-$11.43M-$12.21M
EPS (basic)-0.13-0.11-0.09—-0.08-0.09-0.09—
EPS (diluted)-0.13-0.11-0.09—-0.08-0.09-0.09—
Weighted avg. shares (diluted)159.73M156.60M145.59M—145.10M130.35M117.61M—
Balance sheet
Cash & equivalents$27.85M$54.30M$19.41M$18.91M$56.87M$117.06M$19.37M$34.10M
Short-term investments$271.56M$264.57M$152.37M$169.35M$138.06M$86.83M$83.88M$73.53M
Current assets$305.80M$325.70M$176.12M$191.66M$198.30M$207.23M$105.62M$109.43M
PP&E, net$342,000$336,000$265,000$178,000$213,000$239,000$277,000$157,000
Total assets$310.81M$330.52M$179.61M$193.44M$199.36M$208.34M$107.00M$110.90M
Current liabilities$7.87M$8.74M$7.12M$9.75M$9.04M$9.24M$6.87M$10.51M
Total liabilities$8.06M$9.01M$7.48M$10.20M$9.57M$9.85M$7.55M$11.26M
Shareholders' equity$302.76M$321.51M$172.13M$183.24M$189.79M$198.49M$99.46M$99.64M
Shares outstanding142.53M142.42M128.41M128.31M128.22M121.78M99.89M93.60M
Cash flow statement
Operating cash flow-$19.69M-$17.43M-$16.69M-$7.63M-$10.88M-$10.10M-$13.48M-$9.55M
Capital expenditure$25,000$124,000$102,000$0$12,000——$7,000
Free cash flow-$19.71M-$17.55M-$16.79M-$7.63M-$10.89M——-$9.56M
Investing cash flow-$7.18M-$112.04M$16.96M-$30.61M-$50.94M-$2.61M-$9.95M-$23.87M
Financing cash flow$412,000$164.36M$222,000$284,000$1.63M$110.39M$8.71M$51.47M
Depreciation & amortization$41,000$34,000$34,000$31,000$38,000$38,000$37,000$38,000
Stock-based compensation$3.37M$3.27M$2.19M$1.35M$1.24M$1.38M$1.21M$917,000

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.